A Phase 3 interventional study of single-use autoinjector with a prefilled liquid Avonex syringe and Avonex prefilled syringe via manual IM injection in Multiple Sclerosis, sponsored by Biogen. Completed at 16 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-06-03.
Sponsored by Biogen · Phase 3 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing Interferon beta-1a in Multiple Sclerosis — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, this one is the 16th largest by enrollment, is the only one that started in 2009, is one of 7 in phase 3, and was the 17th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.
Browse Multiple Sclerosis studies →None of the 34 studies testing Interferon beta-1a in Multiple Sclerosis is open now. The open studies under Multiple Sclerosis, anywhere →
Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 8 · Phase 4 15
First in 1999; this study’s year is marked. 1 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 95 is above the median of 50 across 2,205 interventional studies indexed under Multiple Sclerosis.
Median enrollment 85 across the 34 interventional studies. Of the 32 that completed or were terminated, 16 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 34 have an industry lead sponsor. The 10 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
127 studies in Multiple Sclerosis by Biogen: 2 open now, 4 under way, 1 of them phase 3. Of 119 finished, 36 (30%) have results posted.
Among the 127 studies in Multiple Sclerosis by Biogen, this one is the 49th largest by enrollment of the 79 interventional ones that give a count, is one of 4 that started in 2009, is one of 28 in phase 3, and was the 34th registered.
Biogen’s Multiple Sclerosis studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing Interferon beta-1a in Multiple Sclerosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 127 in Multiple Sclerosis:
This tab as a report to print or save as PDF → With an account.
The primary objective of the study was to evaluate the safe and effective use of the single-use autoinjector for the intramuscular (IM) delivery of liquid Avonex® (interferon beta-1a) in participants with multiple sclerosis (MS).
The Main Study was a 4-week treatment period which consisted of 1 Avonex manual injection using a prefilled syringe, followed by 3 Avonex injections using the single-use autoinjector. The Extension Study was designed to provide continuation of treatment with the Avonex single-use autoinjector to eligible participants who completed the Main Study for up to an additional 12 weeks, and to obtain additional safety and preference data for the Avonex single-use autoinjector.
Participants were enrolled under the initial study protocol (Initial Subject Subset); the study was subsequently suspended. Changes were made to the protocol (including modifications to the autoinjector needle), and additional participants were enrolled (Main Subject Subset).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received open label weekly treatment with Avonex 30 mcg intramuscular (IM) injections, provided in Avonex prefilled syringes. In the Main Study, injection #1: administration of Avonex prefilled syringe via manual IM injection on Day 1. Injections #2, #3, and #4: administration of Avonex prefilled syringe using the single-use autoinjector on Days 8, 15, and 22, respectively. In the Extension Study, participants were to continue treatment with the Avonex single-use autoinjector for up to an additional 12 weeks.
Device: single-use autoinjector with a prefilled liquid Avonex syringe · Device: Avonex prefilled syringe via manual IM injection · Drug: BG9418 (interferon beta-1a)
Also known as: Avonex
Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector
A trainer/observer documented the participant's ability to self-inject with the Avonex single-use autoinjector and completed an observation form. Overall success in using the device for each participant was defined as no failures occurring in any step (ie, device set-up, self-administration of injection, and capping/disposal of the device) during the participant's use of the single-use Avonex autoinjector.
Time frame: Day 22
Number of Participants in the Initial Subset Who Were Satisfied With the Avonex Single-Use Autoinjector
Number of participants in the Initial Subset who answered yes to the question "Were you satisfied with this single-use injector?" on the Subject Satisfaction Questionnaire.
Time frame: Day 23
Percentage of Participants With No Erythema, Induration, or Tenderness, and Normal Temperature at the Injection Site After Injection With the Avonex Single-use Autoinjector
The clinician/investigator evaluated the injection site for erythema, induration, and tenderness as none, mild, moderate, or severe after the use of the Avonex single-use autoinjector. Temperature at the injection site was evaluated as normal, warm, or hot. Those participants having no erythema, induration, or tenderness, and normal temperature at the injection site after injection are presented.
Time frame: Day 1, Day 8 through 22 (highest severity reported between Days 8 and 22)
Mean Score for Ease of Use Grading Scale
Participants scored the ease of use of the Avonex manual injector (Day 1) and single-use autoinjector (Days 8, 15, 22) using a scale that ranged from 0 (extremely difficult) to 10 (extremely easy).
Time frame: Day 1, Day 8, Day 15, Day 22
Percentage of Participants Who Rated the Avonex Single-use Autoinjector Printed and DVD Training Materials as Very Effective
Participants evaluated how effective the printed and DVD instructions were in educating how to use the Avonex single-use autoinjector. Participants could choose one of the following descriptive answers: not effective at all, somewhat ineffective, neutral, somewhat effective, or very effective.
Time frame: Day 8, Day 15, Day 22
Mean Score for Initial Subset on Autoinjector Instructions Grading Scale
Participants in the Initial Subset were asked to answer the question "How satisfied are you with the presentation of the autoinjector instructions?" on a rating scale of 0 (extremely dissatisfied) to 10 (extremely satisfied).
Time frame: Day 8
Percentage of Participants Who Indicated No Difficulty With the Injection Procedure of the Manual Injection or the Avonex Single-use Autoinjector
Participants assessed whether they had experienced any difficulty with the procedure in preparing, injecting, removing, and disposing process after each injection with the Avonex single-use autoinjector by answering yes or no to the following question: "Did you have any difficulty with your injection?" The percentage of participants answering no to this question for both the manual injection on Day 1 and the autoinjector on Days 8. 15 and 22 are presented.
Time frame: Day 1, Day 8, Day 15, Day 22
Percentage of Participants Who Indicated a Preference for the Avonex Single-use Autoinjector Over the Manual Avonex Prefilled Syringe
Participants were asked whether they preferred using the Avonex single-use autoinjector over the manual Avonex prefilled syringe. Preference was defined as participants answering yes to the following question: Do you prefer this single-use autoinjector over the manual injection?
Time frame: Day 23
Mean Pain Score After Injection
Participants scored their pain level after the use of the manual prefilled syringe on Day 1 and the Avonex single-use autoinjector on Days 8, 15, and 22 on a scale ranging from 0 (no pain) to 10 (extremely painful).
Time frame: Day 1, Day 8, Day 15, Day 22
Recruitment occurred in the following stages: Main Study (Initial Subset and Main Subset enrolled), and Extension Study. Initial subset participants were withdrawn when the study was suspended. After a protocol amendment, the Main Subset participants were enrolled. Only those in the Main Subset had the option to participate in the Extension Study.
| Milestone | Avonex Single-Use Autoinjector: Initial Subset | Avonex Single-Use Autoinjector: Main Subset |
|---|---|---|
| Started | 21 | 0 |
| Completed manual injection | 21 | 0 |
| Continued with autoinjector injections | 19 | 0 |
| Completed | 7 | 0 |
| Not completed | 14 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Subject was withdrawn | 2 | 0 |
| Withdrew: Study suspension | 11 | 0 |
| Milestone | Avonex Single-Use Autoinjector: Initial Subset | Avonex Single-Use Autoinjector: Main Subset |
|---|---|---|
| Started | 0 | 74 |
| Completed manual injection | 0 | 74 |
| Continued with autoinjector injections | 0 | 72 |
| Completed | 0 | 71 |
| Not completed | 0 | 3 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Noncompliance | 0 | 1 |
| Milestone | Avonex Single-Use Autoinjector: Initial Subset | Avonex Single-Use Autoinjector: Main Subset |
|---|---|---|
| Started | 0 | 64 |
| Completed | 0 | 61 |
| Not completed | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 |
A trainer/observer documented the participant's ability to self-inject with the Avonex single-use autoinjector and completed an observation form. Overall success in using the device for each participant was defined as no failures occurring in any step (ie, device set-up, self-administration of injection, and capping/disposal of the device) during the participant's use of the single-use Avonex autoinjector.
| percentage of participants | Avonex Single-Use Autoinjector: Main Subset |
|---|---|
| Percentage of Participants in the Main Subset With Overall Success Using the Avonex Single-Use Autoinjector | 89 (81 to 96) |
Number of participants in the Initial Subset who answered yes to the question "Were you satisfied with this single-use injector?" on the Subject Satisfaction Questionnaire.
| participants | Avonex Single-Use Autoinjector: Initial Subset |
|---|---|
| Number of Participants in the Initial Subset Who Were Satisfied With the Avonex Single-Use Autoinjector | 14 |
The clinician/investigator evaluated the injection site for erythema, induration, and tenderness as none, mild, moderate, or severe after the use of the Avonex single-use autoinjector. Temperature at the injection site was evaluated as normal, warm, or hot. Those participants having no erythema, induration, or tenderness, and normal temperature at the injection site after injection are presented.
| percentage of participants | Avonex Single-Use Autoinjector: Main Subset | Avonex Single-Use Autoinjector: Initial Subset |
|---|---|---|
| No Erythema | 65 | 95 |
| No Induration | 86 | 100 |
| No Tenderness | 90 | 79 |
| Normal Temperature | 100 | 100 |
Participants scored the ease of use of the Avonex manual injector (Day 1) and single-use autoinjector (Days 8, 15, 22) using a scale that ranged from 0 (extremely difficult) to 10 (extremely easy).
| scores on a scale | Avonex Single-Use Autoinjector: Main Subset | Avonex Single-Use Autoinjector: Initial Subset |
|---|---|---|
| Day 1 (Manual Injection) n=72, 19 | 8.1 ± 2.64 | 7.4 ± 2.41 |
| Day 8 (Autoinjector) n= 72, 18 | 8.9 ± 1.96 | 6.8 ± 3.39 |
| Day 15 (Autoinjector) n=71, 16 | 8.7 ± 2.47 | 6.7 ± 3.07 |
| Day 22 (Autoinjector) n=70, 7 | 9.3 ± 1.87 | 5.9 ± 3.13 |
Participants evaluated how effective the printed and DVD instructions were in educating how to use the Avonex single-use autoinjector. Participants could choose one of the following descriptive answers: not effective at all, somewhat ineffective, neutral, somewhat effective, or very effective.
| percentage of participants | Avonex Single-Use Autoinjector: Main Subset |
|---|---|
| Printed instructions, Day 8; n=68 | 93 |
| DVD, Day 8; n=69 | 88 |
| Printed instructions, Day 15; n=42 | 90 |
| DVD, Day 15; n=10 | 90 |
| Printed instructions, Day 22; n=24 | 92 |
| DVD, Day 22; n=9 | 89 |
Participants in the Initial Subset were asked to answer the question "How satisfied are you with the presentation of the autoinjector instructions?" on a rating scale of 0 (extremely dissatisfied) to 10 (extremely satisfied).
| scores on a scale | Avonex Single-Use Autoinjector: Initial Subset |
|---|---|
| Mean Score for Initial Subset on Autoinjector Instructions Grading Scale | 9.5 ± 0.71 |
Participants assessed whether they had experienced any difficulty with the procedure in preparing, injecting, removing, and disposing process after each injection with the Avonex single-use autoinjector by answering yes or no to the following question: "Did you have any difficulty with your injection?" The percentage of participants answering no to this question for both the manual injection on Day 1 and the autoinjector on Days 8. 15 and 22 are presented.
| percentage of participants | Avonex Single-Use Autoinjector: Main Subset |
|---|---|
| Day 1 (Manual Injection); n=70 | 89 |
| Day 8 (Autoinjector); n=71 | 90 |
| Day 15 (Autoinjector); n=71 | 90 |
| Day 22 (Autoinjector); n=71 | 90 |
Participants were asked whether they preferred using the Avonex single-use autoinjector over the manual Avonex prefilled syringe. Preference was defined as participants answering yes to the following question: Do you prefer this single-use autoinjector over the manual injection?
| percentage of participants | Avonex Single-Use Autoinjector: Main Subset | Avonex Single-Use Autoinjector: Initial Subset |
|---|---|---|
| Percentage of Participants Who Indicated a Preference for the Avonex Single-use Autoinjector Over the Manual Avonex Prefilled Syringe | 94 | 53 |
Participants scored their pain level after the use of the manual prefilled syringe on Day 1 and the Avonex single-use autoinjector on Days 8, 15, and 22 on a scale ranging from 0 (no pain) to 10 (extremely painful).
| scores on a scale | Avonex Single-Use Autoinjector: Main Subset | Avonex Single-Use Autoinjector: Initial Subset |
|---|---|---|
| Day 1 (Manual Injection) n=72, 19 | 1.7 ± 1.76 | 2.5 ± 2.87 |
| Day 8 (Autoinjector) n= 72, 18 | 1.0 ± 1.46 | 1.9 ± 2.19 |
| Day 15 (Autoinjector) n=71, 16 | 1.3 ± 1.64 | 2.1 ± 1.95 |
| Day 22 (Autoinjector) n=70, 7 | 0.7 ± 1.13 | 2.4 ± 2.99 |
Collected over Adverse events (AEs) and serious adverse events (SAEs) treatment-emergent to the autoinjector (from Day 8) through Day 23 (end of Main Study, for the Initial Study Subset), and through Day 107 (end of Extension Period, for the Main Study Subset).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Avonex Single-Use Autoinjector: Main Subset | — | 0/72 (0%) | 33/72 (45.8%) |
| Avonex Single-Use Autoinjector: Initial Subset | — | 0/19 (0%) | 7/19 (36.8%) |
| Event | Avonex Single-Use Autoinjector: Main Subset | Avonex Single-Use Autoinjector: Initial Subset |
|---|---|---|
| Injection Site PainGeneral disorders | 7/72 | 4/19 |
| Injection Site HaematomaGeneral disorders | 6/72 | 1/19 |
| HypoaesthesiaNervous system disorders | 2/72 | 1/19 |
| HeadacheNervous system disorders | 1/72 | 1/19 |
| Nasal CongestionRespiratory, thoracic and mediastinal disorders | 2/72 | 1/19 |
| NauseaGastrointestinal disorders | 1/72 | 1/19 |
| Pain In ExtremityMusculoskeletal and connective tissue disorders | 1/72 | 1/19 |
| Influenza Like IllnessGeneral disorders | 3/72 | 1/19 |
| Injection Site ErythemaGeneral disorders | 3/72 | 1/19 |
| PruritisSkin and subcutaneous tissue disorders | 0/72 | 1/19 |
This table presents the baseline characteristics for both the Initial Subset and Main Subset populations. As represented in the Participant Flow module, these 2 groups participated prior to and after study suspension, respectively; therefore the total column should not be interpreted as cumulative.
| Age, Categorical(Participants) | Avonex Single-Use Autoinjector: Main Subset | Avonex Single-Use Autoinjector: Initial Subset | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 72 | 21 | 93 |
| >=65 years | 2 | 0 | 2 |
| Sex: Female, Male(Participants) | Avonex Single-Use Autoinjector: Main Subset | Avonex Single-Use Autoinjector: Initial Subset | Total |
|---|---|---|---|
| Female | 64 | 18 | 82 |
| Male | 10 | 3 | 13 |
The record gives a start of Jan 2009, a primary completion of Jul 2010 and a completion of Oct 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Interferon beta-1a